“Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial”. 2019. SKIN The Journal of Cutaneous Medicine 3 (November): S17. https://doi.org/10.25251/skin.3.supp.17.